APO Research
Talk to an analyst

APO RESEARCH · REPORT

Fibromyalgia Antidepressant

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Fibromyalgia Antidepressant Industry Growth and Trends Forecast to 2032

31 December 202597 pages

Choose your research edition.

Industry ResearchFibromyalgia Antidepressant Industry Research Report 2026115 pages · $2,950 USDIndustry Growth & TrendsGlobal Fibromyalgia Antidepressant Industry Growth and Trends Forecast to 203297 pages · $3,450 USDMarket StructureGlobal Fibromyalgia Antidepressant Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032184 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Fibromyalgia Antidepressant Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Fibromyalgia Antidepressant Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

The global Fibromyalgia Antidepressant market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Fibromyalgia Antidepressant is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Fibromyalgia Antidepressant is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Fibromyalgia Antidepressant is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Fibromyalgia Antidepressant include Pfizer, AbbVie, Virios Therapeutics, TONIX Pharmaceuticals Holdings, FSD Pharma and Aptinyx, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Fibromyalgia Antidepressant market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Fibromyalgia Antidepressant market size, estimates, and forecasts are presented in terms of sales volume (K Units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Fibromyalgia Antidepressant market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Fibromyalgia Antidepressant.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Fibromyalgia Antidepressant market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Fibromyalgia Antidepressant Market by Company

Pfizer

AbbVie

Virios Therapeutics

TONIX Pharmaceuticals Holdings

FSD Pharma

Aptinyx

Fibromyalgia Antidepressant Segment by Type

Milnacipran HCL

Venlafaxine

Duloxetine HCL

Others

Fibromyalgia Antidepressant Segment by Application

Retail Pharmacies

Online Sales

Drug stores

Hospital Pharmacies

Fibromyalgia Antidepressant Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Fibromyalgia Antidepressant market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Fibromyalgia Antidepressant and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Fibromyalgia Antidepressant.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Fibromyalgia Antidepressant manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Fibromyalgia Antidepressant in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Milnacipran HCL Table 2. Major Company of Venlafaxine Table 3. Major Company of Duloxetine HCL Table 4. Major Company of Others Table 5. Global Fibromyalgia Antidepressant Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 6. Global Fibromyalgia Antidepressant Sales by Type (2021-2026) & (K Units) Table 7. Global Fibromyalgia Antidepressant Sales Market Share in Volume by Type (2021-2026) Table 8. Global Fibromyalgia Antidepressant Sales by Type (2021-2026) & (US$ Million) Table 9. Global Fibromyalgia Antidepressant Sales Market Share in Value by Type (2021-2026) Table 10. Global Fibromyalgia Antidepressant Price by Type (2021-2026) & (US$/Unit) Table 11. Global Fibromyalgia Antidepressant Sales by Type (2027-2032) & (K Units) Table 12. Global Fibromyalgia Antidepressant Sales Market Share in Volume by Type (2027-2032) Table 13. Global Fibromyalgia Antidepressant Sales by Type (2027-2032) & (US$ Million) Table 14. Global Fibromyalgia Antidepressant Sales Market Share in Value by Type (2027-2032) Table 15. Global Fibromyalgia Antidepressant Price by Type (2027-2032) & (US$/Unit) Table 16. North America Fibromyalgia Antidepressant Sales by Type (2021-2026) & (K Units) Table 17. North America Fibromyalgia Antidepressant Sales by Type (2021-2026) & (US$ Million) Table 18. Europe Fibromyalgia Antidepressant Sales by Type (2021-2026) & (K Units) Table 19. Europe Fibromyalgia Antidepressant Sales by Type (2021-2026) & (US$ Million) Table 20. Asia-Pacific Fibromyalgia Antidepressant Sales by Type (2021-2026) & (K Units) Table 21. Asia-Pacific Fibromyalgia Antidepressant Sales by Type (2021-2026) & (US$ Million) Table 22. Latin America Fibromyalgia Antidepressant Sales by Type (2021-2026) & (K Units) Table 23. Latin America Fibromyalgia Antidepressant Sales by Type (2021-2026) & (US$ Million) Table 24. Middle East and Africa Fibromyalgia Antidepressant Sales by Type (2021-2026) & (K Units) Table 25. Middle East and Africa Fibromyalgia Antidepressant Sales by Type (2021-2026) & (US$ Million) Table 26. Fibromyalgia Antidepressant Industry Trends Table 27. Fibromyalgia Antidepressant Industry Drivers Table 28. Fibromyalgia Antidepressant Industry Opportunities and Challenges Table 29. Fibromyalgia Antidepressant Industry Restraints Table 30. Global Fibromyalgia Antidepressant Sales Revenue by Company (US$ Million) & (2021-2026) Table 31. Global Fibromyalgia Antidepressant Revenue Market Share by Company (2021-2026) Table 32. Global Fibromyalgia Antidepressant Sales by Company (2021-2026) & (K Units) Table 33. Global Fibromyalgia Antidepressant Sales Share by Company (2021-2026) Table 34. Global Fibromyalgia Antidepressant Market Price by Company (2021-2026) & (US$/Unit) Table 35. Global Fibromyalgia Antidepressant Industry Company Ranking, 2024 VS 2025 VS 2026 Table 36. Global Fibromyalgia Antidepressant Major Company Production Sites and Headquarters Table 37. Global Fibromyalgia Antidepressant Company, Product Type & Application Table 38. Global Fibromyalgia Antidepressant Company Establishment Date Table 39. Global Company Market Concentration Ratio (CR5 and HHI) Table 40. Global Fibromyalgia Antidepressant by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 41. Global Fibromyalgia Antidepressant Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 42. Global Fibromyalgia Antidepressant Sales by Region (2021-2026) & (K Units) Table 43. Global Fibromyalgia Antidepressant Sales Market Share in Volume by Region (2021-2026) Table 44. Global Fibromyalgia Antidepressant Sales by Region (2021-2026) & (US$ Million) Table 45. Global Fibromyalgia Antidepressant Sales Market Share in Value by Region (2021-2026) Table 46. Global Fibromyalgia Antidepressant Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 47. Global Fibromyalgia Antidepressant Sales by Region (2027-2032) & (K Units) Table 48. Global Fibromyalgia Antidepressant Sales Market Share in Volume by Region (2027-2032) Table 49. Global Fibromyalgia Antidepressant Sales by Region (2027-2032) & (US$ Million) Table 50. Global Fibromyalgia Antidepressant Sales Market Share in Value by Region (2027-2032) Table 51. Global Fibromyalgia Antidepressant Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2027-2032) Table 52. Global Fibromyalgia Antidepressant Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 53. Global Fibromyalgia Antidepressant Sales by Application (2021-2026) & (K Units) Table 54. Global Fibromyalgia Antidepressant Sales Market Share in Volume by Application (2021-2026) Table 55. Global Fibromyalgia Antidepressant Sales by Application (2021-2026) & (US$ Million) Table 56. Global Fibromyalgia Antidepressant Sales Market Share in Value by Application (2021-2026) Table 57. Global Fibromyalgia Antidepressant Price by Application (2021-2026) & (US$/Unit) Table 58. Global Fibromyalgia Antidepressant Sales by Application (2027-2032) & (K Units) Table 59. Global Fibromyalgia Antidepressant Sales Market Share in Volume by Application (2027-2032) Table 60. Global Fibromyalgia Antidepressant Sales by Application (2027-2032) & (US$ Million) Table 61. Global Fibromyalgia Antidepressant Sales Market Share in Value by Application (2027-2032) Table 62. Global Fibromyalgia Antidepressant Price by Application (2027-2032) & (US$/Unit) Table 63. North America Fibromyalgia Antidepressant Sales by Application (2021-2026) & (K Units) Table 64. North America Fibromyalgia Antidepressant Sales by Application (2021-2026) & (US$ Million) Table 65. Europe Fibromyalgia Antidepressant Sales by Application (2021-2026) & (K Units) Table 66. Europe Fibromyalgia Antidepressant Sales by Application (2021-2026) & (US$ Million) Table 67. Asia-Pacific Fibromyalgia Antidepressant Sales by Application (2021-2026) & (K Units) Table 68. Asia-Pacific Fibromyalgia Antidepressant Sales by Application (2021-2026) & (US$ Million) Table 69. Latin America Fibromyalgia Antidepressant Sales by Application (2021-2026) & (K Units) Table 70. Latin America Fibromyalgia Antidepressant Sales by Application (2021-2026) & (US$ Million) Table 71. Middle East and Africa Fibromyalgia Antidepressant Sales by Application (2021-2026) & (K Units) Table 72. Middle East and Africa Fibromyalgia Antidepressant Sales by Application (2021-2026) & (US$ Million) Table 73. Pfizer Company Information Table 74. Pfizer Business Overview Table 75. Pfizer Fibromyalgia Antidepressant Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. Pfizer Fibromyalgia Antidepressant Product Portfolio Table 77. Pfizer Recent Development Table 78. AbbVie Company Information Table 79. AbbVie Business Overview Table 80. AbbVie Fibromyalgia Antidepressant Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 81. AbbVie Fibromyalgia Antidepressant Product Portfolio Table 82. AbbVie Recent Development Table 83. Virios Therapeutics Company Information Table 84. Virios Therapeutics Business Overview Table 85. Virios Therapeutics Fibromyalgia Antidepressant Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 86. Virios Therapeutics Fibromyalgia Antidepressant Product Portfolio Table 87. Virios Therapeutics Recent Development Table 88. TONIX Pharmaceuticals Holdings Company Information Table 89. TONIX Pharmaceuticals Holdings Business Overview Table 90. TONIX Pharmaceuticals Holdings Fibromyalgia Antidepressant Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. TONIX Pharmaceuticals Holdings Fibromyalgia Antidepressant Product Portfolio Table 92. TONIX Pharmaceuticals Holdings Recent Development Table 93. FSD Pharma Company Information Table 94. FSD Pharma Business Overview Table 95. FSD Pharma Fibromyalgia Antidepressant Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 96. FSD Pharma Fibromyalgia Antidepressant Product Portfolio Table 97. FSD Pharma Recent Development Table 98. Aptinyx Company Information Table 99. Aptinyx Business Overview Table 100. Aptinyx Fibromyalgia Antidepressant Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 101. Aptinyx Fibromyalgia Antidepressant Product Portfolio Table 102. Aptinyx Recent Development Table 103. North America Fibromyalgia Antidepressant Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 104. North America Fibromyalgia Antidepressant Sales by Country (2021-2026) & (K Units) Table 105. North America Fibromyalgia Antidepressant Sales Market Share by Country (2021-2026) Table 106. North America Fibromyalgia Antidepressant Sales Forecast by Country (2027-2032) & (K Units) Table 107. North America Fibromyalgia Antidepressant Sales Market Share Forecast by Country (2027-2032) Table 108. North America Fibromyalgia Antidepressant Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 109. North America Fibromyalgia Antidepressant Market Size by Country (2021-2026) & (US$ Million) Table 110. North America Fibromyalgia Antidepressant Market Share by Country (2021-2026) Table 111. North America Fibromyalgia Antidepressant Market Size Forecast by Country (2027-2032) & (US$ Million) Table 112. North America Fibromyalgia Antidepressant Market Share Forecast by Country (2027-2032) Table 113. Europe Fibromyalgia Antidepressant Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 114. Europe Fibromyalgia Antidepressant Sales by Country (2021-2026) & (K Units) Table 115. Europe Fibromyalgia Antidepressant Sales Market Share by Country (2021-2026) Table 116. Europe Fibromyalgia Antidepressant Sales Forecast by Country (2027-2032) & (K Units) Table 117. Europe Fibromyalgia Antidepressant Sales Market Share Forecast by Country (2027-2032) Table 118. Europe Fibromyalgia Antidepressant Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 119. Europe Fibromyalgia Antidepressant Market Size by Country (2021-2026) & (US$ Million) Table 120. Europe Fibromyalgia Antidepressant Market Share by Country (2021-2026) Table 121. Europe Fibromyalgia Antidepressant Market Size Forecast by Country (2027-2032) & (US$ Million) Table 122. Europe Fibromyalgia Antidepressant Market Share Forecast by Country (2027-2032) Table 123. Asia-Pacific Fibromyalgia Antidepressant Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 124. Asia-Pacific Fibromyalgia Antidepressant Sales by Country (2021-2026) & (K Units) Table 125. Asia-Pacific Fibromyalgia Antidepressant Sales Market Share by Country (2021-2026) Table 126. Asia-Pacific Fibromyalgia Antidepressant Sales Forecast by Country (2027-2032) & (K Units) Table 127. Asia-Pacific Fibromyalgia Antidepressant Sales Market Share Forecast by Country (2027-2032) Table 128. Asia-Pacific Fibromyalgia Antidepressant Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 129. Asia-Pacific Fibromyalgia Antidepressant Market Size by Country (2021-2026) & (US$ Million) Table 130. Asia-Pacific Fibromyalgia Antidepressant Market Share by Country (2021-2026) Table 131. Asia-Pacific Fibromyalgia Antidepressant Market Size Forecast by Country (2027-2032) & (US$ Million) Table 132. Asia-Pacific Fibromyalgia Antidepressant Market Share Forecast by Country (2027-2032) Table 133. Latin America Fibromyalgia Antidepressant Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 134. Latin America Fibromyalgia Antidepressant Sales by Country (2021-2026) & (K Units) Table 135. Latin America Fibromyalgia Antidepressant Sales Market Share by Country (2021-2026) Table 136. Latin America Fibromyalgia Antidepressant Sales Forecast by Country (2027-2032) & (K Units) Table 137. Latin America Fibromyalgia Antidepressant Sales Market Share Forecast by Country (2027-2032) Table 138. Latin America Fibromyalgia Antidepressant Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 139. Latin America Fibromyalgia Antidepressant Market Size by Country (2021-2026) & (US$ Million) Table 140. Latin America Fibromyalgia Antidepressant Market Share by Country (2021-2026) Table 141. Latin America Fibromyalgia Antidepressant Market Size Forecast by Country (2027-2032) & (US$ Million) Table 142. Latin America Fibromyalgia Antidepressant Market Share Forecast by Country (2027-2032) Table 143. Middle East and Africa Fibromyalgia Antidepressant Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 144. Middle East and Africa Fibromyalgia Antidepressant Sales by Country (2021-2026) & (K Units) Table 145. Middle East and Africa Fibromyalgia Antidepressant Sales Market Share by Country (2021-2026) Table 146. Middle East and Africa Fibromyalgia Antidepressant Sales Forecast by Country (2027-2032) & (K Units) Table 147. Middle East and Africa Fibromyalgia Antidepressant Sales Market Share Forecast by Country (2027-2032) Table 148. Middle East and Africa Fibromyalgia Antidepressant Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 149. Middle East and Africa Fibromyalgia Antidepressant Market Size by Country (2021-2026) & (US$ Million) Table 150. Middle East and Africa Fibromyalgia Antidepressant Market Share by Country (2021-2026) Table 151. Middle East and Africa Fibromyalgia Antidepressant Market Size Forecast by Country (2027-2032) & (US$ Million) Table 152. Middle East and Africa Fibromyalgia Antidepressant Market Share Forecast by Country (2027-2032) Table 153. Key Raw Materials Table 154. Raw Materials Key Suppliers Table 155. Fibromyalgia Antidepressant Distributors List Table 156. Fibromyalgia Antidepressant Customers List Table 157. Research Programs/Design for This Report Table 158. Authors List of This Report Table 159. Secondary Sources Table 160. Primary Sources List of Figures Figure 1. Fibromyalgia Antidepressant Image Figure 2. Global Fibromyalgia Antidepressant Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Fibromyalgia Antidepressant Market Size (2021-2032) & (US$ Million) Figure 4. Global Fibromyalgia Antidepressant Sales (2021-2032) & (K Units) Figure 5. Milnacipran HCL Image Figure 6. Global Milnacipran HCL Sales YoY Growth (2021-2032) & (K Units) Figure 7. Venlafaxine Image Figure 8. Global Venlafaxine Sales YoY Growth (2021-2032) & (K Units) Figure 9. Duloxetine HCL Image Figure 10. Global Duloxetine HCL Sales YoY Growth (2021-2032) & (K Units) Figure 11. Others Image Figure 12. Global Others Sales YoY Growth (2021-2032) & (K Units) Figure 13. Global Fibromyalgia Antidepressant Market Size Overview by Type (2021-2032) & (US$ Million) Figure 14. Global Fibromyalgia Antidepressant Market Share by Type 2025 VS 2032 Figure 15. North America Fibromyalgia Antidepressant Sales Market Share in Volume by Type in 2025 Figure 16. North America Fibromyalgia Antidepressant Sales Market Share in Value by Type in 2025 Figure 17. Europe Fibromyalgia Antidepressant Sales Market Share in Volume by Type in 2025 Figure 18. Europe Fibromyalgia Antidepressant Sales Market Share in Value by Type in 2025 Figure 19. Asia-Pacific Fibromyalgia Antidepressant Sales Market Share in Volume by Type in 2025 Figure 20. Asia-Pacific Fibromyalgia Antidepressant Sales Market Share in Value by Type in 2025 Figure 21. Latin America Fibromyalgia Antidepressant Sales Market Share in Volume by Type in 2025 Figure 22. Latin America Fibromyalgia Antidepressant Sales Market Share in Value by Type in 2025 Figure 23. Middle East and Africa Fibromyalgia Antidepressant Sales Market Share in Volume by Type in 2025 Figure 24. Middle East and Africa Fibromyalgia Antidepressant Sales Market Share in Value by Type in 2025 Figure 25. Global Top 5 and 10 Fibromyalgia Antidepressant Players Market Share by Revenue in 2025 Figure 26. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 27. Retail Pharmacies Image Figure 28. Global Retail Pharmacies Sales YoY Growth (2021-2032) & (K Units) Figure 29. Online Sales Image Figure 30. Global Online Sales Sales YoY Growth (2021-2032) & (K Units) Figure 31. Drug stores Image Figure 32. Global Drug stores Sales YoY Growth (2021-2032) & (K Units) Figure 33. Hospital Pharmacies Image Figure 34. Global Hospital Pharmacies Sales YoY Growth (2021-2032) & (K Units) Figure 35. Global Fibromyalgia Antidepressant Market Size Overview by Application (2021-2032) & (US$ Million) Figure 36. Global Fibromyalgia Antidepressant Market Share by Application 2025 VS 2032 Figure 37. North America Fibromyalgia Antidepressant Sales Market Share in Volume by Application in 2025 Figure 38. North America Fibromyalgia Antidepressant Sales Market Share in Value by Application in 2025 Figure 39. Europe Fibromyalgia Antidepressant Sales Market Share in Volume by Application in 2025 Figure 40. Europe Fibromyalgia Antidepressant Sales Market Share in Value by Application in 2025 Figure 41. Asia-Pacific Fibromyalgia Antidepressant Sales Market Share in Volume by Application in 2025 Figure 42. Asia-Pacific Fibromyalgia Antidepressant Sales Market Share in Value by Application in 2025 Figure 43. Latin America Fibromyalgia Antidepressant Sales Market Share in Volume by Application in 2025 Figure 44. Latin America Fibromyalgia Antidepressant Sales Market Share in Value by Application in 2025 Figure 45. Middle East and Africa Fibromyalgia Antidepressant Sales Market Share in Volume by Application in 2025 Figure 46. Middle East and Africa Fibromyalgia Antidepressant Sales Market Share in Value by Application in 2025 Figure 47. North America Fibromyalgia Antidepressant Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 48. North America Fibromyalgia Antidepressant Sales Share by Country: 2021 VS 2025 VS 2032 Figure 49. North America Fibromyalgia Antidepressant Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 50. North America Fibromyalgia Antidepressant Market Share by Country: 2021 VS 2025 VS 2032 Figure 51. Europe Fibromyalgia Antidepressant Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 52. Europe Fibromyalgia Antidepressant Sales Share by Country: 2021 VS 2025 VS 2032 Figure 53. Europe Fibromyalgia Antidepressant Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 54. Europe Fibromyalgia Antidepressant Market Share by Country: 2021 VS 2025 VS 2032 Figure 55. Asia-Pacific Fibromyalgia Antidepressant Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 56. Asia-Pacific Fibromyalgia Antidepressant Sales Share by Country: 2021 VS 2025 VS 2032 Figure 57. Asia-Pacific Fibromyalgia Antidepressant Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Asia-Pacific Fibromyalgia Antidepressant Market Share by Country: 2021 VS 2025 VS 2032 Figure 59. Latin America Fibromyalgia Antidepressant Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 60. Latin America Fibromyalgia Antidepressant Sales Share by Country: 2021 VS 2025 VS 2032 Figure 61. Latin America Fibromyalgia Antidepressant Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 62. Latin America Fibromyalgia Antidepressant Market Share by Country: 2021 VS 2025 VS 2032 Figure 63. Middle East and Africa Fibromyalgia Antidepressant Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 64. Middle East and Africa Fibromyalgia Antidepressant Sales Share by Country: 2021 VS 2025 VS 2032 Figure 65. Middle East and Africa Fibromyalgia Antidepressant Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 66. Middle East and Africa Fibromyalgia Antidepressant Market Share by Country: 2021 VS 2025 VS 2032 Figure 67. Fibromyalgia Antidepressant Value Chain Figure 68. Key Raw Materials Price Figure 69. Manufacturing Cost Structure Figure 70. Fibromyalgia Antidepressant Production Mode & Process Figure 71. Direct Comparison with Distribution Share Figure 72. Distributors Profiles Figure 73. Years Considered Figure 74. Research Process Figure 75. Key Executives Interviewed

Scope & coverage.

Types
  • Milnacipran HCL
  • Venlafaxine
  • Duloxetine HCL
  • Others
Applications
  • Retail Pharmacies
  • Online Sales
  • Drug stores
  • Hospital Pharmacies
Companies covered
  • Pfizer
  • AbbVie
  • Virios Therapeutics
  • TONIX Pharmaceuticals Holdings
  • FSD Pharma
  • Aptinyx

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Fibromyalgia Antidepressant Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Fibromyalgia Antidepressant Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Fibromyalgia Antidepressant Market by Type
  6. 1.3.1 Milnacipran HCL
  7. 1.3.2 Venlafaxine
  8. 1.3.3 Duloxetine HCL
  9. 1.3.4 Others
  10. 1.4 Global Fibromyalgia Antidepressant Market Size by Type
  11. 1.4.1 Global Fibromyalgia Antidepressant Market Size Overview by Type (2021-2032)
  12. 1.4.2 Global Fibromyalgia Antidepressant Historic Market Size Review by Type (2021-2026)
  13. 1.4.3 Global Fibromyalgia Antidepressant Forecasted Market Size by Type (2027-2032)
  14. 1.5 Key Regions Market Size by Type
  15. 1.5.1 North America Fibromyalgia Antidepressant Sales Breakdown by Type (2021-2026)
  16. 1.5.2 Europe Fibromyalgia Antidepressant Sales Breakdown by Type (2021-2026)
  17. 1.5.3 Asia-Pacific Fibromyalgia Antidepressant Sales Breakdown by Type (2021-2026)
  18. 1.5.4 South America Fibromyalgia Antidepressant Sales Breakdown by Type (2021-2026)
  19. 1.5.5 Middle East and Africa Fibromyalgia Antidepressant Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Fibromyalgia Antidepressant Industry Trends
  2. 2.2 Fibromyalgia Antidepressant Industry Drivers
  3. 2.3 Fibromyalgia Antidepressant Industry Opportunities and Challenges
  4. 2.4 Fibromyalgia Antidepressant Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Fibromyalgia Antidepressant Revenue (2021-2026)
  2. 3.2 Global Top Players by Fibromyalgia Antidepressant Sales (2021-2026)
  3. 3.3 Global Top Players by Fibromyalgia Antidepressant Price (2021-2026)
  4. 3.4 Global Fibromyalgia Antidepressant Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Fibromyalgia Antidepressant Major Company Production Sites & Headquarters
  6. 3.6 Global Fibromyalgia Antidepressant Company, Product Type & Application
  7. 3.7 Global Fibromyalgia Antidepressant Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Fibromyalgia Antidepressant Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Fibromyalgia Antidepressant Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Fibromyalgia Antidepressant Tier 1, Tier 2, and Tier 3
4 Fibromyalgia Antidepressant Regional Status and Outlook
  1. 4.1 Global Fibromyalgia Antidepressant Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Fibromyalgia Antidepressant Historic Market Size by Region
  3. 4.2.1 Global Fibromyalgia Antidepressant Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Fibromyalgia Antidepressant Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Fibromyalgia Antidepressant Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Fibromyalgia Antidepressant Forecasted Market Size by Region
  7. 4.3.1 Global Fibromyalgia Antidepressant Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Fibromyalgia Antidepressant Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Fibromyalgia Antidepressant Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Fibromyalgia Antidepressant by Application
  1. 5.1 Fibromyalgia Antidepressant Market by Application
  2. 5.1.1 Retail Pharmacies
  3. 5.1.2 Online Sales
  4. 5.1.3 Drug stores
  5. 5.1.4 Hospital Pharmacies
  6. 5.2 Global Fibromyalgia Antidepressant Market Size by Application
  7. 5.2.1 Global Fibromyalgia Antidepressant Market Size Overview by Application (2021-2032)
  8. 5.2.2 Global Fibromyalgia Antidepressant Historic Market Size Review by Application (2021-2026)
  9. 5.2.3 Global Fibromyalgia Antidepressant Forecasted Market Size by Application (2027-2032)
  10. 5.3 Key Regions Market Size by Application
  11. 5.3.1 North America Fibromyalgia Antidepressant Sales Breakdown by Application (2021-2026)
  12. 5.3.2 Europe Fibromyalgia Antidepressant Sales Breakdown by Application (2021-2026)
  13. 5.3.3 Asia-Pacific Fibromyalgia Antidepressant Sales Breakdown by Application (2021-2026)
  14. 5.3.4 South America Fibromyalgia Antidepressant Sales Breakdown by Application (2021-2026)
  15. 5.3.5 Middle East and Africa Fibromyalgia Antidepressant Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Pfizer
  2. 6.1.1 Pfizer Company Information
  3. 6.1.2 Pfizer Business Overview
  4. 6.1.3 Pfizer Fibromyalgia Antidepressant Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Pfizer Fibromyalgia Antidepressant Product Portfolio
  6. 6.1.5 Pfizer Recent Developments
  7. 6.2 AbbVie
  8. 6.2.1 AbbVie Company Information
  9. 6.2.2 AbbVie Business Overview
  10. 6.2.3 AbbVie Fibromyalgia Antidepressant Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 AbbVie Fibromyalgia Antidepressant Product Portfolio
  12. 6.2.5 AbbVie Recent Developments
  13. 6.3 Virios Therapeutics
  14. 6.3.1 Virios Therapeutics Company Information
  15. 6.3.2 Virios Therapeutics Business Overview
  16. 6.3.3 Virios Therapeutics Fibromyalgia Antidepressant Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Virios Therapeutics Fibromyalgia Antidepressant Product Portfolio
  18. 6.3.5 Virios Therapeutics Recent Developments
  19. 6.4 TONIX Pharmaceuticals Holdings
  20. 6.4.1 TONIX Pharmaceuticals Holdings Company Information
  21. 6.4.2 TONIX Pharmaceuticals Holdings Business Overview
  22. 6.4.3 TONIX Pharmaceuticals Holdings Fibromyalgia Antidepressant Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 TONIX Pharmaceuticals Holdings Fibromyalgia Antidepressant Product Portfolio
  24. 6.4.5 TONIX Pharmaceuticals Holdings Recent Developments
  25. 6.5 FSD Pharma
  26. 6.5.1 FSD Pharma Company Information
  27. 6.5.2 FSD Pharma Business Overview
  28. 6.5.3 FSD Pharma Fibromyalgia Antidepressant Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 FSD Pharma Fibromyalgia Antidepressant Product Portfolio
  30. 6.5.5 FSD Pharma Recent Developments
  31. 6.6 Aptinyx
  32. 6.6.1 Aptinyx Company Information
  33. 6.6.2 Aptinyx Business Overview
  34. 6.6.3 Aptinyx Fibromyalgia Antidepressant Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 Aptinyx Fibromyalgia Antidepressant Product Portfolio
  36. 6.6.5 Aptinyx Recent Developments
7 North America by Country
  1. 7.1 North America Fibromyalgia Antidepressant Sales by Country
  2. 7.1.1 North America Fibromyalgia Antidepressant Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Fibromyalgia Antidepressant Sales by Country (2021-2026)
  4. 7.1.3 North America Fibromyalgia Antidepressant Sales Forecast by Country (2027-2032)
  5. 7.2 North America Fibromyalgia Antidepressant Market Size by Country
  6. 7.2.1 North America Fibromyalgia Antidepressant Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Fibromyalgia Antidepressant Market Size by Country (2021-2026)
  8. 7.2.3 North America Fibromyalgia Antidepressant Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Fibromyalgia Antidepressant Sales by Country
  2. 8.1.1 Europe Fibromyalgia Antidepressant Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Fibromyalgia Antidepressant Sales by Country (2021-2026)
  4. 8.1.3 Europe Fibromyalgia Antidepressant Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Fibromyalgia Antidepressant Market Size by Country
  6. 8.2.1 Europe Fibromyalgia Antidepressant Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Fibromyalgia Antidepressant Market Size by Country (2021-2026)
  8. 8.2.3 Europe Fibromyalgia Antidepressant Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Fibromyalgia Antidepressant Sales by Country
  2. 9.1.1 Asia-Pacific Fibromyalgia Antidepressant Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Fibromyalgia Antidepressant Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Fibromyalgia Antidepressant Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Fibromyalgia Antidepressant Market Size by Country
  6. 9.2.1 Asia-Pacific Fibromyalgia Antidepressant Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Fibromyalgia Antidepressant Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Fibromyalgia Antidepressant Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Fibromyalgia Antidepressant Sales by Country
  2. 10.1.1 South America Fibromyalgia Antidepressant Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Fibromyalgia Antidepressant Sales by Country (2021-2026)
  4. 10.1.3 South America Fibromyalgia Antidepressant Sales Forecast by Country (2027-2032)
  5. 10.2 South America Fibromyalgia Antidepressant Market Size by Country
  6. 10.2.1 South America Fibromyalgia Antidepressant Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Fibromyalgia Antidepressant Market Size by Country (2021-2026)
  8. 10.2.3 South America Fibromyalgia Antidepressant Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Fibromyalgia Antidepressant Sales by Country
  2. 11.1.1 Middle East and Africa Fibromyalgia Antidepressant Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Fibromyalgia Antidepressant Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Fibromyalgia Antidepressant Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Fibromyalgia Antidepressant Market Size by Country
  6. 11.2.1 Middle East and Africa Fibromyalgia Antidepressant Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Fibromyalgia Antidepressant Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Fibromyalgia Antidepressant Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Fibromyalgia Antidepressant Value Chain Analysis
  2. 12.1.1 Fibromyalgia Antidepressant Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Fibromyalgia Antidepressant Production Mode & Process
  7. 12.2 Fibromyalgia Antidepressant Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Fibromyalgia Antidepressant Distributors
  10. 12.2.3 Fibromyalgia Antidepressant Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst